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Abstract
Purpose: To provide an overview of the clinical presentation, diagnosis, and
management of exercise-induced bronchospasm (EIB) without underlying
asthma.
Data sources: Case presentation and review of the EIB Landmark Survey.
Conclusions: EIB is a common and well-described occurrence in patients with
asthma, as well as in patients with no overt respiratory condition. Treatment
with a short-acting beta-agonist before starting exercise is effective, yet this
treatment approach is underutilized in the majority of patients with asthma.
Implications for practice: This case highlights the implications of under-
managed EIB and the disconnect between healthcare provider recommenda-
tions and the beliefs and behaviors in patients with EIB. Inhaled short-acting
beta-agonists can attenuate EIB in 80%–95% of patients and are effective dur-
ing 2–3 h of exercise. Patients with a compromised level of physical activity be-
cause of EIB who do not respond to conventional treatment strategies should
be referred to a respiratory specialist for diagnostic evaluation and conﬁrma-
tion of underlying asthma. Nurse practitioners should remain vigilant to iden-
tify untreated EIB and ensure that affected patients understand the condition
and appropriate treatment options.
Overview
Up to 90% of patients with asthma are reported to have
exercise-induced asthma (EIA) or exercise-induced bron-
chospasm (EIB; McFadden & Gilbert, 1994), and as many
as 12%–15% of patients without asthma may develop
EIB (Gotshall, 2002), usually during or within 20 min
of ﬁnishing moderate to vigorous exercise. Rather than
seeking medical diagnosis and management, individuals
with asthma or EIB may decide not to participate in ex-
ercise, leaving them at higher risk for other conditions,
such as obesity, which may impact their overall health
and lifestyle habits (Dogra, Baker, & Ardern, 2009). The
widespread incidence of EIB, particularly in patients with
asthma but also in those with no overt respiratory condi-
tion, suggests that healthcare professionals will encounter
such patients regularly in their day-to-day practice.
Although the pathogenesis of EIB is not fully eluci-
dated, it is probably caused by exercise-induced hyper-
ventilation and corresponding changes in airway physiol-
ogy (Weiler et al., 2010). A history of cough, shortness of
breath, chest pain or tightness, wheezing, or endurance
problems during exercise suggests EIB. However, use of
history alone has been shown to both underdiagnose and
overdiagnose the problem (McKenzie et al., 2002; Tan
& Spector, 2002). An exercise challenge is often used to
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establish the diagnosis, although additional indirect and
direct bronchoprovocation tests can also be used to con-
ﬁrm diagnosis (Parsons, 2010; Stack & Hakemi, 2011).
Typically, a 10%–15% decrease in peak expiratory ﬂow
or forced expiratory volume in 1 s (FEV1)a f t e ra ni n d i r e c t
or direct bronchoprovocation test is compatible with EIB
(U.S. Department of Health and Human Services, 2007;
Weiler et al., 2010).
The recent EIB Landmark Survey (www.
eiblandmarksurvey.com, 2009) was a multisurvey initia-
tive that reported on subjects with and without a diagno-
sis of asthma with an objective of better understanding
the impact of exercise-related respiratory symptoms. As
part of this initiative, a general public survey (N = 1000)
included individuals who have no diagnosis of asthma
(86%) and those who have a diagnosis of asthma or who
currently take asthma medications (14%). Result high-
lights included the fact that 5% were diagnosed as having
EIA or EIB (29% of the asthma population and 2% of
the nonasthma population), while another 24% of the
general adult population reported experiencing at least
one of six exercise-related respiratory symptoms during
or immediately after exercising: shortness of breath,
wheezing, coughing, difﬁculty taking a deep breath,
noisy breathing, or chest tightness. There was a weak
correlation between exercise-related respiratory symp-
toms and diagnosis of EIA or EIB (r = .045, p = .077). The
proportion of adults diagnosed with EIA or EIB was 7%
for those who experienced 1 or 2 of these EIB symptoms.
The diagnosis of EIA or EIB increased to 11% with three
symptoms, 19% with four symptoms, 24% with ﬁve
symptoms, and 35% with all six symptoms. However, the
majority (65%) of adults who experienced respiratory
symptoms during or shortly after exercise or physical
exertion had never been diagnosed with EIA or EIB.
Treatment for EIB is well established (U.S. Department
of Health and Human Services, 2007). Prophylactic use
of a short-acting beta-2 agonist (SABA) inhaler, such
as albuterol, levalbuterol, or pirbuterol, before starting
moderate exercise is highly effective in 80%–95% of pa-
tients with EIB (Milgrom & Taussig, 1999; U.S. Depart-
ment of Health and Human Services, 2007). However,
despite this widely accepted approach to treatment, the
EIB Landmark Survey reported that less than 25% of
asthma patients with exercise-related respiratory symp-
toms use quick-relief medicine before exercising. Thus,
many patients fail to effectively manage their EIB. In
the EIB Landmark Survey, 96% of healthcare providers,
but only 57% of patients, agreed that quick-relief med-
ications should be taken before exercise to reduce the
chances of an asthma attack.
Next, we present the case of a patient with EIB without
underlying asthma, illustrating the impact that this condi-
tion can have when not managed effectively. All possible
identifying information has been excluded.
Case study
A 34-year-old female visits her nurse practitioner (NP)
with complaints of fatigue and lethargy. She is over-
weight, with a body mass index of 28, and has a history
of depression, for which she has been taking a selective
serotonin reuptake inhibitor since the birth of her second
child 5 years ago. Her blood pressure is 120/80 mmHg,
and routine laboratory tests reveal elevated serum triglyc-
eride and low high-density lipoprotein values. She has
no other remarkable clinical history, including no his-
tory of asthma, recurrent bronchitis, or tobacco use. The
patient denies cough, chest pain, palpitations, peripheral
edema, and nocturnal awakening with respiratory symp-
toms. Additional questioning reveals that the patient has
avoided recreational activity since adolescence because it
often left her feeling out of breath, with mild wheezing,
unable to keep up with her peers. She has gained 40 lb
since the birth of her second child, which she feels has
“slowed her down.”
A review of the patient’s medical history reveals that
until recently she has led a largely sedentary home life
and has only recently begun to participate in recreational
exercise because of her commitment as a single mother
to her two daughters. She has also started taking brief
walks with her children around the track, which re-
sults in shortness of breath within 5–8 min of begin-
ning exercise. She is not accustomed to this new level of
physical activity and is experiencing shortness of breath,
chest tightness, and wheezing on exhalation no more
than twice a week, which resolves if she rests or drinks
coffee.
Physical examination
Head, eye, ear, nose, and throat examinations were un-
remarkable, and chest examination showed normal ex-
cursion and was clear upon auscultation. Heart sounds
showed regular rate and rhythm, with no S3 or S4 mur-
mur or gallop. No signs of peripheral edema were present,
and the skin was normal.
Differential diagnosis
Common differential diagnoses when a young adult pa-
tient complains of shortness of breath include asthma and
other pulmonary diseases, cardiovascular disease, vocal
cord dysfunction, obesity, poor conditioning, and dysp-
nea as a result of anemia.
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Figure 1 Spirometry results showing pre- and post-exercise challenge.
Diagnostic testing and treatment
The patient was referred for further diagnostic testing.
Chest x-ray was normal and complete blood count within
normal limits. An exercise challenge revealed oxygen sat-
uration of 99% at rest and 98% after a 6-min walk. Pul-
monary function tests were ordered and revealed normal
ﬂow volume loop, normal lung volumes, and FEV1 (90%
of predicted). While her baseline spirometry reading was
normal, a second spirometry after exercise challenge re-
vealed a signiﬁcant decrease (15%) in FEV1 (Figure 1).
The patient’s NP makes a presumptive diagnosis of EIB.
Patients with suspected EIB should be evaluated with
a detailed history and physical examination (including
ear, nose, and throat and cardiac and chest examinations)
and lung function measurements before and after SABA
administration. A decrease of at least 10% in FEV1 after
exercise is sufﬁcient to make the diagnosis of EIB, espe-
cially if symptoms accompany the drop in FEV1 (U.S. De-
partment of Health and Human Services, 2007; Weiler
et al., 2010). A diagnosis of reversible airway obstruc-
tion is made if FEV1 improves by 12% (and 200 mL) at
15 min after SABA administration (Crapo et al., 2000).
Often, EIB can be prevented by use of a SABA inhaled
within 15 min before exercise; some authors suggest that
response to this therapy can serve as a basis for a diagno-
sis of EIB. In many patients, bronchial hyperresponsive-
ness should be evaluated with an exercise challenge or a
surrogate challenge (e.g., with cold air hyperventilation,
methacholine, adenosine 5-monophosphate, or mannitol
challenge).
For patients in whom spirometric testing does not
deﬁnitively diagnose EIB, formal bronchoprovocation
testing may be performed. Given greater availability,
an exercise challenge is more typically used. Exercise
and eucapneic voluntary hyperventilation (EVH) test-
ing are examples of indirect airway challenges that act
by causing the release of endogenous mediators of air-
way smooth muscle contraction. In athletes, EVH test-
ing, performed in a specialized pulmonary function lab-
oratory, is the most sensitive test for diagnosing EIB.
In patients with risk of coronary heart disease, cardiac
monitoring and immediate availability of resuscitation re-
sources are required. Thus, healthcare practitioners of-
ten seek other types of challenges for these adults. A
mannitol bronchial challenge test (AridolTM)h a sr e c e n t l y
been approved in the United States for the assessment
of bronchial hyperresponsiveness in patients 6 years of
age or older and has been used to diagnose EIB. Re-
sponses to challenges with other indirect-acting stim-
uli (adenosine 5-monophosphate, hypertonic saline, and
cold dry air) tend to correlate with each other, and sev-
eral have been studied as surrogate challenge agents for
EIB. This is in contrast to the action of methacholine
and histamine, which provoke bronchoconstriction by
direct action on airway smooth muscle (Weiler et al.,
2010).
Treatment for EIB is well established (Millward, Tan-
ner, & Brown, 2010; Stack & Hakemi, 2011). The
National Asthma Education and Prevention Program Ex-
pert Panel (EPR-3) convened by the National Heart,
Lung, and Blood Institute reviewed the evidence for the
treatment and management of EIB. Shortly before exer-
cise, a SABA administered for the prevention of EIB may
be helpful for 2–3 h. Two puffs of a SABA, such as al-
buterol, levalbuterol, or pirbuterol, before exercise are
effective in more than 80% of cases. Long-acting beta-
2 agonists (LABAs) have a longer duration of action and
c a nb ep r o t e c t i v ef o ru pt o1 2h .H o w e v e r ,w h e nL A B A s
are administered on a daily basis, there is some short-
ening of the duration of protection, even in patients us-
ing inhaled corticosteroids. The EPR-3 guidelines recom-
mend that frequent and long-term use of LABAs for EIB
should be discouraged. Such use may disguise poorly con-
trolled persistent asthma, which should be managed with
a daily anti-inﬂammatory. The Food and Drug Adminis-
tration recently required a label change for both approved
LABAs in the United States: use without a long-term
controller, such as an inhaled steroid, is contraindicated.
Leukotriene receptor antagonists can attenuate EIB in up
to 50% of patients, but onset of action is generally hours
after administration. Given that the patient’s respiratory
symptoms occur only with exercise and given the high
degree of effectiveness with SABAs, the NP recommends
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the prophylactic use of a SABA before undertaking any
physical activity.
According to the EPR-3 guidelines, EIB should limit
neither participation nor success in vigorous activities.
The NP informs the patient that there is no need to avoid
recreational activity and, indeed, that with judicious use
of her new inhaler she should be able to participate fully
in physical activity and may also gain control over her
exercise-induced respiratory symptoms. The NP teaches
the patient that a warm-up period before exercise may
reduce the degree of EIB and that a mask or scarf over the
mouth may attenuate cold air-induced EIB (U.S. Depart-
ment of Health and Human Services, 2007). Increased
physical activity may also lead to reduced body mass in-
dex and blood pressure. The NP asks the patient to call
with an update within 2 weeks and recommends a for-
mal evaluation by an asthma specialist to further assess
her for respiratory symptoms.
Peak ﬂow monitoring, after establishing the patient’s
best baseline peak ﬂow, can be used as needed to mon-
itor patients with symptoms of EIB. All patients, regard-
less of the presence of asthma, should be encouraged to
participate in a conditioning exercise program consisting
of moderate to vigorous exercise lasting at least 20 min
3–4 times each week. Exercise recommendations should
be complemented by nutrition and dietary monitoring
and appropriate weight reduction targets in applicable pa-
tients (Haskell et al., 2007).
Case resolution
The patient returns to her NP 4 weeks later and reports
that a follow-up visit with an asthma specialist revealed
no underlying asthma. She further reports prevention of
respiratory symptoms with use of albuterol pressurized
metered dose inhaler before exercise, which she is us-
ing no more than twice a week. She reports accepting
a job that requires frequent walking between buildings,
walking the track at the middle school with her daughters
at least twice a week without any respiratory symptoms,
and losing 4 lb. She reports feeling more energetic, more
positive about her health, and is pleased with her weight
loss and control of EIB symptoms.
Discussion
This case highlights the implications of undermanaged
EIB and the possible consequences of decreased physi-
cal activity or sedentary lifestyle, which can lead to car-
diometabolic disease (Gaesser, Angadi, & Sawyer, 2011;
Leiter et al., 2011; McGuire, Janssen, & Ross, 2009;
Thorp, Owen, Neuhaus, & Dunstan, 2011). To minimize
the risks of obesity and cardiac and metabolic disease in
later life, it is important that EIB should not limit partic-
ipation in physical activity, particularly as effective treat-
ments are readily available. Inhaled SABAs can attenu-
ate EIB in 80%–95% of patients with asthma (Milgrom &
Taussig, 1999) and are effective for 2–3 h during exercise;
preexercise treatment with a SABA, possibly in combina-
tion with long-term controller therapy, is recommended.
Furthermore, Guidelines for the Diagnosis and Man-
agement of Asthma (U.S. Department of Health and
Human Services, 2007) indicate that patients with EIB
should be monitored regularly to ensure their symptoms,
including exercise-associated shortness of breath, chest
tightness, cough, and wheezing, are well controlled and
are not representative of uncontrolled asthma. Patients
with persistent symptoms should be evaluated for an ap-
propriate modiﬁcation of treatment, including addition of
a long-term controller medication (U.S. Department of
Health and Human Services, 2007). Patients with a com-
promised level of physical activity because of EIB who
do not respond to these conventional treatment strate-
gies should be referred to an asthma specialist for further
evaluation and treatment.
Conclusions
EIB is a well established, easily managed, and of-
ten underdiagnosed condition. Patients with EIB should
be encouraged to participate fully in physical exercise.
Healthcare providers should remain vigilant to identify
untreated EIB and ensure that appropriate advice and
treatment options are fully discussed with affected
patients.
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